| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor
|
Hara, S.
|
|
|
16 |
6 |
p. 928-933
|
artikel
|
| 2 |
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
|
Norum, J.
|
|
|
16 |
6 |
p. 909-914
|
artikel
|
| 3 |
Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients
|
Etienne-Grimaldi, M.-C.
|
|
|
16 |
6 |
p. 934-941
|
artikel
|
| 4 |
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
|
Desai, A.A.
|
|
|
16 |
6 |
p. 958-965
|
artikel
|
| 5 |
Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review
|
Hoei-Hansen, C.E.
|
|
|
16 |
6 |
p. 863-868
|
artikel
|
| 6 |
Corrections to “Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO”
|
|
|
|
16 |
6 |
p. 993
|
artikel
|
| 7 |
Corrections to “Workgroup III: facilitating screening for colorectal cancer: quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)”
|
|
|
|
16 |
6 |
p. 993
|
artikel
|
| 8 |
Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study)
|
Bonneterre, J.
|
|
|
16 |
6 |
p. 915-922
|
artikel
|
| 9 |
Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group
|
Cleeland, C.S.
|
|
|
16 |
6 |
p. 972-980
|
artikel
|
| 10 |
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study
|
Feher, O.
|
|
|
16 |
6 |
p. 899-908
|
artikel
|
| 11 |
Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis
|
Chen, C.-C.
|
|
|
16 |
6 |
p. 988-989
|
artikel
|
| 12 |
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype
|
Ruzzo, A.
|
|
|
16 |
6 |
p. 887-892
|
artikel
|
| 13 |
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
|
Kalofonos, H.P.
|
|
|
16 |
6 |
p. 869-877
|
artikel
|
| 14 |
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
|
Punt, C.J.A.
|
|
|
16 |
6 |
p. 845-846
|
artikel
|
| 15 |
Limitations of Wright formula estimates of renal function
|
Dooley, M.J.
|
|
|
16 |
6 |
p. 989-990
|
artikel
|
| 16 |
Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium
|
Brenner, H.
|
|
|
16 |
6 |
p. 981-986
|
artikel
|
| 17 |
Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide
|
Brada, M.
|
|
|
16 |
6 |
p. 942-949
|
artikel
|
| 18 |
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial †
|
Comella, P.
|
|
|
16 |
6 |
p. 878-886
|
artikel
|
| 19 |
Predictors of prescription of morphine for severe cancer pain by physicians in Korea
|
Yun, Y.H.
|
|
|
16 |
6 |
p. 966-971
|
artikel
|
| 20 |
Quality of cancer care
|
Gorodokin, G.I.
|
|
|
16 |
6 |
p. 991
|
artikel
|
| 21 |
Reply to the letter “Limitations of bedside estimates of renal function”, by M. J. Dooley and S. G. Poole (doi:10.1093/annonc/mdi173)
|
Marx, G.M.
|
|
|
16 |
6 |
p. 990
|
artikel
|
| 22 |
Reply to the Letter to the Editor on Safety of sentinel node biopsy in pregnant patients, by G. Dubernard et al. (Ann Oncol 2005; 16: 987)
|
Paganelli, G.
|
|
|
16 |
6 |
p. 987-988
|
artikel
|
| 23 |
Safety of sentinel node biopsy in pregnant patients
|
Dubernard, G.
|
|
|
16 |
6 |
p. 987
|
artikel
|
| 24 |
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
|
Manegold, C.
|
|
|
16 |
6 |
p. 923-927
|
artikel
|
| 25 |
Table of Contents
|
|
|
|
16 |
6 |
p. ii-iii
|
artikel
|
| 26 |
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group
|
Bafaloukos, D.
|
|
|
16 |
6 |
p. 950-957
|
artikel
|
| 27 |
The Complete Guide to Relieving Cancer Pain and Suffering
|
Wilson, R.
|
|
|
16 |
6 |
p. 992
|
artikel
|
| 28 |
Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results
|
Mosolits, S.
|
|
|
16 |
6 |
p. 847-862
|
artikel
|
| 29 |
Tumour budding detected by laminin-5 γ2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer
|
Nilsson, P.J.
|
|
|
16 |
6 |
p. 893-898
|
artikel
|
Tijdschrift beschrijving